Prevalence of metabolic syndrome in four phenotypes of PCOS and its relationship with androgenic components among Iranian women: A cross-sectional study.
Hyperandrogenism.
Metabolic syndrome
Polycystic ovary syndrome
Journal
International journal of reproductive biomedicine
ISSN: 2476-4108
Titre abrégé: Int J Reprod Biomed
Pays: Iran
ID NLM: 101679102
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
08
06
2019
revised:
15
10
2019
accepted:
21
10
2019
entrez:
5
6
2020
pubmed:
5
6
2020
medline:
5
6
2020
Statut:
epublish
Résumé
Polycystic ovary syndrome (PCOS) increases the risk of metabolic syndrome (MetS). Insulin resistance (IR) plays a major role in the pathophysiology of both PCOS and MetS. This study was designed to compare the prevalence of MetS among different phenotypes of PCOS and its relationship with androgenic components. 182 participants eligible for this five-group comparative study were selected by convenience sampling method. They were classified according to the Rotterdam criteria: clinical and/or biochemical hyperandrogenism (H) + PCOS on ultrasound (P) + ovulation disorders (O) (n = 41), clinical and/or biochemical H + PCOS on P (n = 33), PCOS on P + O (n = 40), clinical and/or biochemical H + O (n = 37), and control (without PCOS) (n = 31). MetS was measured based on the National Cholesterol Education Program Adult Treatment Panel III criteria. Androgenic components included free-androgen-index (FAI), total-testosterone (TT) level and sex-hormone-binding-globulin (SHBG). A significant difference was observed between the study groups in terms of MetS prevalence (p = 0.01). In phenotype H+P+O, there was a statistically significant positive association between TG and TT, and a significant negative association between SBP and DBP with SHBG. In phenotype O+P, WC was inversely associated with SHBG. In phenotype H+O, FBS and TG were positively associated with FAI but HDL was inversely associated with FAI. Moreover, WC and DBP were positively associated with TT in phenotype H+O. No associations were detected between MetS parameters and androgenic components in other PCOS subjects (phenotype H+P) and in the control group. TT was significantly higher in the PCOS group suffering from MetS (p = 0.04). According to the research results, hyperandrogenic components are potent predictors of metabolic disorders. Thus, we suggest that MetS screening is required for the prevention of MetS and its related complications in PCOS women.
Sections du résumé
BACKGROUND
BACKGROUND
Polycystic ovary syndrome (PCOS) increases the risk of metabolic syndrome (MetS). Insulin resistance (IR) plays a major role in the pathophysiology of both PCOS and MetS.
OBJECTIVE
OBJECTIVE
This study was designed to compare the prevalence of MetS among different phenotypes of PCOS and its relationship with androgenic components.
MATERIALS AND METHODS
METHODS
182 participants eligible for this five-group comparative study were selected by convenience sampling method. They were classified according to the Rotterdam criteria: clinical and/or biochemical hyperandrogenism (H) + PCOS on ultrasound (P) + ovulation disorders (O) (n = 41), clinical and/or biochemical H + PCOS on P (n = 33), PCOS on P + O (n = 40), clinical and/or biochemical H + O (n = 37), and control (without PCOS) (n = 31). MetS was measured based on the National Cholesterol Education Program Adult Treatment Panel III criteria. Androgenic components included free-androgen-index (FAI), total-testosterone (TT) level and sex-hormone-binding-globulin (SHBG).
RESULTS
RESULTS
A significant difference was observed between the study groups in terms of MetS prevalence (p = 0.01). In phenotype H+P+O, there was a statistically significant positive association between TG and TT, and a significant negative association between SBP and DBP with SHBG. In phenotype O+P, WC was inversely associated with SHBG. In phenotype H+O, FBS and TG were positively associated with FAI but HDL was inversely associated with FAI. Moreover, WC and DBP were positively associated with TT in phenotype H+O. No associations were detected between MetS parameters and androgenic components in other PCOS subjects (phenotype H+P) and in the control group. TT was significantly higher in the PCOS group suffering from MetS (p = 0.04).
CONCLUSION
CONCLUSIONS
According to the research results, hyperandrogenic components are potent predictors of metabolic disorders. Thus, we suggest that MetS screening is required for the prevention of MetS and its related complications in PCOS women.
Identifiants
pubmed: 32494764
doi: 10.18502/ijrm.v13i4.6888
pmc: PMC7218672
doi:
Types de publication
Journal Article
Langues
eng
Pagination
253-264Informations de copyright
Copyright © 2020 Zaeemzadeh et al.
Déclaration de conflit d'intérêts
The authors declare that there are no conflicts of interest.
Références
J Hum Reprod Sci. 2015 Oct-Dec;8(4):202-8
pubmed: 26752855
J Endocrinol. 2011 Mar;208(3):293-300
pubmed: 21173020
Circulation. 2009 Oct 20;120(16):1640-5
pubmed: 19805654
Hum Reprod. 2004 Jan;19(1):41-7
pubmed: 14688154
Reprod Health. 2015 Jan 16;12:7
pubmed: 25595199
Gynecol Endocrinol. 2009 May;25(5):335-43
pubmed: 19903040
Akush Ginekol (Sofiia). 2010;49(4):32-7
pubmed: 20734639
Endocrinol Metab Clin North Am. 2014 Mar;43(1):123-47
pubmed: 24582095
Minerva Endocrinol. 2007 Mar;32(1):35-47
pubmed: 17353865
Fertil Steril. 2009 Aug;92(2):626-34
pubmed: 18706545
Hum Reprod. 2009 Mar;24(3):710-7
pubmed: 19095675
J Endocrinol Invest. 2013 Jul-Aug;36(7):478-84
pubmed: 23211631
Clin Endocrinol (Oxf). 2007 Jul;67(1):129-34
pubmed: 17465999
J Clin Endocrinol Metab. 1961 Nov;21:1440-7
pubmed: 13892577
Arch Endocrinol Metab. 2016 Feb 23;60(3):199-204
pubmed: 26910626
Eur J Obstet Gynecol Reprod Biol. 2014 Jan;172:51-5
pubmed: 24220143
Fertil Steril. 2014 Mar;101(3):840-5
pubmed: 24424368
Arch Iran Med. 2010 May;13(3):243-4
pubmed: 20433230
Int J Fertil Steril. 2016 Jan-Mar;9(4):490-6
pubmed: 26985336
Eur J Endocrinol. 2006 Jan;154(1):141-5
pubmed: 16382003
BJOG. 2009 Nov;116(12):1633-9
pubmed: 19781047
J Hum Reprod Sci. 2013 Jul;6(3):194-200
pubmed: 24347934
Gynecol Endocrinol. 2007 Oct;23(10):604-9
pubmed: 17852429
J Clin Endocrinol Metab. 1996 Mar;81(3):952-60
pubmed: 8772557
Reprod Biol Endocrinol. 2011 Mar 25;9:39
pubmed: 21435276
Eur J Obstet Gynecol Reprod Biol. 2018 May;224:60-65
pubmed: 29550643
Reprod Biol Endocrinol. 2016 Oct 18;14(1):67
pubmed: 27756332
J Eur Acad Dermatol Venereol. 2011 Jan;25(1):43-8
pubmed: 20456560
Clin Endocrinol (Oxf). 2014 Jul;81(1):93-9
pubmed: 24428207
PLoS One. 2014 Jun 05;9(6):e99252
pubmed: 24901345
Acta Obstet Gynecol Scand. 2015 May;94(5):494-500
pubmed: 25711494
PLoS One. 2014 Oct 13;9(10):e108263
pubmed: 25310562